286 related articles for article (PubMed ID: 28547734)
1. Systemic Therapy for Soft Tissue Sarcoma: Proposals for the Optimal Use of Pazopanib, Trabectedin, and Eribulin.
Kawai A; Yonemori K; Takahashi S; Araki N; Ueda T
Adv Ther; 2017 Jul; 34(7):1556-1571. PubMed ID: 28547734
[TBL] [Abstract][Full Text] [Related]
2. Trabectedin in advanced soft tissue sarcoma: case series.
Demirci U; Buyukberber S; Yetisyigit T; Dizdar O; Benekli M; Alkis N; Coskun U;
J BUON; 2012; 17(3):591-2. PubMed ID: 23033305
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of trabectedin in advanced soft tissue sarcoma: beyond lipo- and leiomyosarcoma.
De Sanctis R; Marrari A; Marchetti S; Mussi C; Balzarini L; Lutman FR; Daolio P; Bastoni S; Bertuzzi AF; Quagliuolo V; Santoro A
Drug Des Devel Ther; 2015; 9():5785-91. PubMed ID: 26604682
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness analysis of pazopanib in second-line treatment of advanced soft tissue sarcoma in Spain.
Villa G; Hernández-Pastor LJ; Guix M; Lavernia J; Cuesta M
Clin Transl Oncol; 2015 Jan; 17(1):24-33. PubMed ID: 24981588
[TBL] [Abstract][Full Text] [Related]
5. Contemporary Therapy for Advanced Soft-Tissue Sarcomas in Adults: A Review.
Pang A; Carbini M; Maki RG
JAMA Oncol; 2016 Jul; 2(7):941-7. PubMed ID: 27148906
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of pharmacological interventions in second- or later-line treatment of patients with advanced soft tissue sarcoma: a systematic review.
Sharma S; Takyar S; Manson SC; Powell S; Penel N
BMC Cancer; 2013 Aug; 13():385. PubMed ID: 23937858
[TBL] [Abstract][Full Text] [Related]
7. Trabectedin in soft tissue sarcomas.
Petek BJ; Loggers ET; Pollack SM; Jones RL
Mar Drugs; 2015 Feb; 13(2):974-83. PubMed ID: 25686274
[TBL] [Abstract][Full Text] [Related]
8. Heterogeneous and Rare: Toward Histology-Specific Treatment of Soft-Tissue Sarcoma.
Azvolinsky A
J Natl Cancer Inst; 2016 Jun; 108(6):djw161. PubMed ID: 27257028
[No Abstract] [Full Text] [Related]
9. Trabectedin in patients with metastatic soft tissue sarcoma: a retrospective single center analysis.
Schur S; Lamm W; Köstler WJ; Hoetzenecker K; Nemecek E; Schwameis K; Klepetko W; Windhager R; Brodowicz T
Anticancer Drugs; 2013 Aug; 24(7):725-30. PubMed ID: 23728219
[TBL] [Abstract][Full Text] [Related]
10. In brief: Two Drugs for soft-tissue sarcoma.
Med Lett Drugs Ther; 2016 May; 58(1494):e62. PubMed ID: 27148925
[No Abstract] [Full Text] [Related]
11. The Danish experience with trabectedin treatment for metastatic sarcoma: Importance of hyponatremia.
Schack LH; Mouritsen LS; Elowsson C; Krarup-Hansen A; Safwat A
Acta Oncol; 2015 Jan; 54(1):34-40. PubMed ID: 25263179
[TBL] [Abstract][Full Text] [Related]
12. Trabectedin : a review of its use in the management of soft tissue sarcoma and ovarian cancer.
Carter NJ; Keam SJ
Drugs; 2007; 67(15):2257-76. PubMed ID: 17927287
[TBL] [Abstract][Full Text] [Related]
13. Trabectedin: Ecteinascidin 743, Ecteinascidin-743, ET 743, ET-743, NSC 684766.
Drugs R D; 2006; 7(5):317-28. PubMed ID: 16922593
[TBL] [Abstract][Full Text] [Related]
14. Combination of trabectedin and gemcitabine for advanced soft tissue sarcomas: results of a phase I dose escalating trial of the German Interdisciplinary Sarcoma Group (GISG).
Kasper B; Reichardt P; Pink D; Sommer M; Mathew M; Rauch G; Hohenberger P
Mar Drugs; 2015 Jan; 13(1):379-88. PubMed ID: 25591040
[TBL] [Abstract][Full Text] [Related]
15. Optimizing the use of trabectedin for advanced soft tissue sarcoma in daily clinical practice.
Le Cesne A; Reichardt P
Future Oncol; 2015; 11(11 Suppl):3-14. PubMed ID: 26043310
[TBL] [Abstract][Full Text] [Related]
16. The Austrian experience with trabectedin in non-selected patients with metastatic soft tissue sarcoma (STS).
Ploner F; Lamm W; Schur S; Eisterer W; Kühr T; Lindorfer A; Tinchon C; Köstler WJ; Szkandera J; Brodowicz T
J Cancer Res Clin Oncol; 2013 Aug; 139(8):1337-42. PubMed ID: 23666164
[TBL] [Abstract][Full Text] [Related]
17. Trabectedin for the treatment of soft tissue sarcomas.
De Sanctis R; Marrari A; Santoro A
Expert Opin Pharmacother; 2016 Aug; 17(11):1569-77. PubMed ID: 27328277
[TBL] [Abstract][Full Text] [Related]
18. The safety and efficacy of trabectedin for the treatment of liposarcoma or leiomyosarcoma.
Saponara M; Stacchiotti S; Gronchi A
Expert Rev Anticancer Ther; 2016 May; 16(5):473-84. PubMed ID: 27043847
[TBL] [Abstract][Full Text] [Related]
19. Trabectedin in soft tissue sarcomas.
Brodowicz T
Future Oncol; 2014 Jun; 10(8 Suppl):s1-5. PubMed ID: 25048043
[TBL] [Abstract][Full Text] [Related]
20. Trabectedin in patients with advanced soft tissue sarcoma: a retrospective national analysis of the French Sarcoma Group.
Le Cesne A; Ray-Coquard I; Duffaud F; Chevreau C; Penel N; Bui Nguyen B; Piperno-Neumann S; Delcambre C; Rios M; Chaigneau L; Le Maignan C; Guillemet C; Bertucci F; Bompas E; Linassier C; Olivier T; Kurtz JE; Even C; Cousin P; Yves Blay J;
Eur J Cancer; 2015 Apr; 51(6):742-50. PubMed ID: 25727882
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
